Fluoroquinolones (FQ) Project

Clostridium difficile infection (CDI) is a critical public health issue for which new prevention strategies are urgently needed. The proposed study will evaluate the effectiveness and implementation of a fluoroquinolone preprescription authorization as an antibiotic stewardship strategy to target and prevent CDI, promote appropriate antibiotic use, and reduce the transmission of resistant bacteria. This work will contribute to the long-term goal of reducing the burden of CDI, which is an essential step in improving the safety and quality of healthcare.

Nasia Safdar, MD, PhD
School of Medicine and Public Health
University of Wisconsin – Madison

Roger Brown, PhD
Clinical Health Science
University of Wisconsin – Madison

Vishala Parmasad, MBBS, MS, PhD
Associate Scientist
Infectious Disease Staff
Clinical Science Center
University of Wisconsin-Madison

Pascale Carayon, PhD
Procter & Gamble Bascom Professor in Total Quality
Department of Industrial and Systems Engineering
Director, Center for Quality and Productivity Improvement
University of Wisconsin-Madison

Aurora Pop-Vicas, MD, MPH
Assistant Professor
School of Medicine and Public Health
University of Wisconsin – Madison

Lucas Schulz, PharmD, BCPS
Clinical Pharmacist
University of Wisconsin Hospital and Clinics

Teresa Thuemling
Wisconsin Institute for Healthcare System Engineering



Musuuza, J., Hundt, A.S., Carayon, P., Christensen, K., Ngam, C., Haun, N. and Safdar, N. “Implementation of a Clostridioides difficile prevention bundle: Understanding common, unique, and conflicting work system barriers and facilitators for sub-process design” To be published in Infection Control & Hospital Epidemiology, 2019. PMC7212912